Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

12 May 2020 Evaluate
Glenmark Pharmaceuticals has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India.

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020. 

Glenmark has successfully developed the API and the formulations for the product through its inhouse R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.  The molecule if commercialized, will be marketed under the brand name ‘FabiFlu’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1955.40 7.80 (0.40%)
18-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1746.00
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 910.00
Lupin 2119.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×